GeneLink (OTCMKTS:GNLKQ – Get Free Report) and Arcellx (NASDAQ:ACLX – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.
Profitability
This table compares GeneLink and Arcellx’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
GeneLink | N/A | N/A | N/A |
Arcellx | -37.23% | -12.42% | -7.30% |
Institutional and Insider Ownership
96.0% of Arcellx shares are held by institutional investors. 14.2% of GeneLink shares are held by insiders. Comparatively, 6.2% of Arcellx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
GeneLink | 0 | 0 | 0 | 0 | N/A |
Arcellx | 0 | 0 | 13 | 1 | 3.07 |
Arcellx has a consensus price target of $88.50, suggesting a potential downside of 1.97%.
Volatility and Risk
GeneLink has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.
Valuation & Earnings
This table compares GeneLink and Arcellx”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
GeneLink | N/A | N/A | N/A | N/A | N/A |
Arcellx | $144.75 million | 33.37 | -$70.69 million | ($1.03) | -87.65 |
GeneLink has higher earnings, but lower revenue than Arcellx.
Summary
Arcellx beats GeneLink on 5 of the 9 factors compared between the two stocks.
About GeneLink
GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.
About Arcellx
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company’s preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Receive News & Ratings for GeneLink Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneLink and related companies with MarketBeat.com's FREE daily email newsletter.